683 Capital Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-29,660
| Closed | -$148K | – | 159 |
|
|
2024
Q1 | $148K | Sell |
29,660
-40,340
| -58% | -$250K | 0.01% | 102 |
|
|
2023
Q4 | $471K | Sell |
70,000
-18,333
| -21% | -$161K | 0.04% | 96 |
|
|
2023
Q3 | $808K | Sell |
88,333
-36,667
| -29% | -$737K | 0.06% | 104 |
|
|
2023
Q2 | $2.64M | Sell |
125,000
-6,667
| -5% | -$205K | 0.19% | 90 |
|
|
2023
Q1 | $3.54M | Buy |
131,667
+27,834
| +27% | +$1.29M | 0.26% | 95 |
|
|
2022
Q4 | $3.68M | Sell |
103,833
-40,492
| -28% | -$4.86M | 0.31% | 77 |
|
|
2022
Q3 | $32.6M | Buy |
144,325
+15,492
| +12% | +$3.81M | 2.52% | 9 |
|
|
2022
Q2 | $24.4M | Buy |
128,833
+16,333
| +15% | +$3.29M | 1.72% | 15 |
|
|
2022
Q1 | $28M | Buy |
112,500
+2,500
| +2% | +$395K | 1.5% | 12 |
|
|
2021
Q4 | $17.1M | Buy |
110,000
+4,167
| +4% | +$806K | 0.63% | 38 |
|
|
2021
Q3 | $21.2M | Buy |
105,833
+7,500
| +8% | +$1.78M | 0.83% | 34 |
|
|
2021
Q2 | $25.1M | Buy |
98,333
+8,880
| +10% | +$2.22M | 0.87% | 29 |
|
|
2021
Q1 | $23.8M | Hold |
89,453
| – | – | 1.26% | 23 |
|
|
2020
Q4 | $33M | Buy |
89,453
+2,023
| +2% | +$580K | 1.56% | 16 |
|
|
2020
Q3 | $21.4M | Buy |
87,430
+15,535
| +22% | +$4.83M | 1.56% | 16 |
|
|
2020
Q2 | $20.7M | Buy |
71,895
+3,895
| +6% | +$1.15M | 1.66% | 14 |
|
|
2020
Q1 | $13.9M | Buy |
68,000
+6,333
| +10% | +$2.02M | 1.63% | 17 |
|
|
2019
Q4 | $27.6M | Sell |
61,667
-351
| -0.6% | -$125K | 3.15% | 5 |
|
|
2019
Q3 | $19.1M | Buy |
62,018
+834
| +1% | +$271K | 2.12% | 14 |
|
|
2019
Q2 | $19.5M | Buy |
61,184
+7,500
| +14% | +$2.6M | 1.77% | 15 |
|
|
2019
Q1 | $22.5M | Hold |
53,684
| – | – | 2.04% | 12 |
|
|
2018
Q4 | $16.4M | Buy |
53,684
+32,643
| +155% | +$10.5M | 0.99% | 24 |
|
|
2018
Q3 | $7.58M | Buy |
21,041
+11,198
| +114% | +$3.83M | 0.49% | 46 |
|
|
2018
Q2 | $3.6M | Buy |
9,843
+3,333
| +51% | +$1.19M | 0.24% | 65 |
|
|
2018
Q1 | $1.92M | Buy |
+6,510
| New | +$1.92M | 0.17% | 82 |
|
Other funds holding EIGR
683 Capital Management's EIGR Position: Q2 2024 in Review
683 Capital Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2024, closing a stake of 29,660 shares — an estimated $148K sold.
683 Capital Management first reported a position in EIGR in Q1 2018 and held it in 25 quarters. The position peaked at $33M in Q4 2020. 2 funds tracked by Wall St. Rank hold EIGR as of Q2 2024.
- 683 Capital Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
- 683 Capital Management sold 29,660 Eiger BioPharmaceuticals, Inc. shares in Q2 2024, an estimated $148K.
- 683 Capital Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2018 and held it in 25 quarters.
- 683 Capital Management's Eiger BioPharmaceuticals, Inc. position peaked at $33M in Q4 2020.
- 2 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2024.
Based on 683 Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.